AI                                                   sarcoma(133)
 _________________________________________________________________
  adriamycin...... 50 mg/sqm IV push on day 1.
  ifosfamide...... 5,000 mg/sqm IV over 24 h, followed by mesna 
                   rescue.
  FREQUENCY....... Repeat cycle every 3 weeks.

  reference...
    Schutte J.  Mouridsen HT.  Stewart W.  Santoro A.  van 
    Oosterom AT.  Somers R.  Blackledge G.  Verweij J.  
    Dombernowsky P.  Thomas D.  et al. Ifosfamide plus doxorubicin 
    in previously untreated patients with advanced soft tissue 
    sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. 
    European Journal of Cancer.  26(5):558-61, 1990. 
  abstract...
    The objective of this phase II trial was to assess the 
    therapeutic activity and toxicity of doxorubicin plus 
    ifosfamide in previously untreated patients with advanced soft 
    tissue sarcoma. Treatment was doxorubicin 50 mg/m2 followed by 
    a 24 h infusion of ifosfamide 5 g/m2 plus mesna 2.5 g/m2 
    repeated every 3 weeks until disease progression or 
    unacceptable toxicity occurred. Of 203 patients entered, 175 
    were evaluable for response. The response rate was 35% (95% CI 
    28-42%), with 9% of the patients achieving a complete 
    remission and 26% a partial remission. The median time to 
    progression was 29 weeks for all evaluable patients, and 67, 
    40 and 28 weeks for complete and partial responders and 
    patients with stable disease, respectively. The median 
    duration of survival was 58 weeks. Myelosuppression was the 
    dose-limiting toxicity, resulting in leukopenia (WHO grade 3 
    and 4) in 73% of evaluable treatment courses. Other 
    side-effects were rare and usually well manageable.